MedTrace Logo

POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC

NCT02845908 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-04-23

No results posted yet for this study

Summary

The aim of this study was to compare the efficacy and safety of POF, FOLFOX, and FOLFOX plus paclitaxel(ip) as first-line treatment in AGC a phase II clinical trial.

Conditions

  • Malignant Neoplasm of Stomach Stage IV

Interventions

DRUG

POF

Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU

DRUG

FOLFOX

Oxaliplatin plus Leucovorin plus 5-FU

DRUG

FOLFOX plus PAC(ip)

FOLFOX plus intraperitoneally PAC

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Principal Investigators

  • Rongbo Lin, MD · Fujian Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2018-05-31
Completion
2020-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02845908 on ClinicalTrials.gov